Alzheimer's disease is a progressive neurodegenerative disorder that affects
cognition, memory, and neuronal loss. Treatment strategies remain largely
underdeveloped, despite numerous studies. The chapter reviews the most recent case
studies and patents to further novel therapeutic approaches in the treatment of AD.
Case studies can depict the potential to exemplify the patient's response in the course of
such therapy, where personal treatment choices are considered in conjunction with the
efficacy of newly introduced therapies. Patents are the indicators of innovative drug
discovery, biomarkers, and neuroprotective strategies. We focus on patents covering
Multi-Target Directed Ligands (MTDLs), monoclonal antibodies, and small molecules
targeting amyloid-beta (Aβ) and tau proteins. We also scan patents centered around
cholinesterase inhibitors, neuroinflammation modulators, and techniques in gene
therapy. Case studies that involve success stories of drug development in clinical
settings, along with personalized medicine approaches, are also examined. New
biotechnological interventions like drug delivery systems via nanotechnology and AIbased diagnostic tools are emerging to transform AD treatment. Furthermore,
regulatory policies and intellectual property rights also create an atmosphere conducive
to speeding or slowing the commercialization of innovative products for AD. Within
view, this chapter gives an integrated view of current patents with a case study of the
management of AD concerning their real-world applications, as well as current
discoveries in its management.
Keywords: Alzheimer’s disease, Amyloid-beta, Artificial intelligence, Biomarkers, Case studies, Cholinesterase inhibitors, Drug discovery, Gene therapy, Neurodegeneration, Neuroinflammation, Patents, Personalized medicine, Tau protein.
